Pancreatic cancer patients may not necessarily live 5 years on Tegio after surgery. Pancreatic cancer is a highly malignant tumor with a poor overall prognosis, often with no obvious symptoms in the early stages, and often in the middle to late stages when detected. Surgery is the preferred treatment for this disease, and the survival period is usually around 2 years. After surgery, single-agent chemotherapy with Tegretol can be used to slow the progression of the disease, but the treatment is generally effective. If the patient cannot be removed by surgery, overall survival is even shorter, potentially around six months or one year. At this time, taking Tegio single-agent chemotherapy is even less effective. It is recommended that patients choose appropriate treatment under the guidance of a doctor to actively treat the disease in order to prolong the survival period.